Gastric cancer
Conditions
Interventions
Single-port laparoscopic distal gastrectomy (with mobile double suspension technique) group:Single-Port Laparoscopic Distal Gastrectomy with Mobile Double Suspension Technique
Traditional laparoscopic distal gastrectomy group:Conventional Multi-Port Laparoscopic Distal Gastrectomy
Sponsors
Yunnan Cancer Hospital (Peking University Cancer Hospital Yunnan Hospital / The Third Affiliated Hospital of Kunming Medical University)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Voluntarily participate in the trial and provide written informed consent; (2) Age > 18 years and < 80 years, regardless of gender; (3) Patients diagnosed by gastroscopic biopsy pathology with adenocarcinoma of the gastric antrum or lower body of the stomach, clinical TNM stage cT1-4aN0/+M0, and requiring surgical treatment; (4) Preoperative ECOG performance status score of 0 or 1; (5) Preoperative ASA score of I-III; (6) Body mass index (BMI) <= 30 kg/m^2; (7) No concurrent other malignant tumors; (8) No history of gastrectomy.
Exclusion criteria
Exclusion criteria: (1) History of previous abdominal surgery or extensive intra-abdominal adhesions. (2) History of unstable angina, myocardial infarction, cerebral infarction, or cerebral hemorrhage within the past 6 months. (3) History of psychological, psychiatric, or neurological disorders. (4) Women who are pregnant, planning to become pregnant, or currently breastfeeding. (5) Patients with cachexia or severe malnutrition. (6) Presence of surgical contraindications such as coagulation dysfunction, HIV antibody positivity, or poorly controlled severe infections. (7) Patients with other comorbidities (e.g., significant abnormalities in liver or kidney function) or concomitant medication use that, in the investigator's judgment, may affect the study outcomes. (8) Requirement for simultaneous surgical treatment of other diseases. (9) Known allergy to the materials of surgical instruments, or a history of allergic predisposition. (10) Any other condition deemed unsuitable for participation in this clinical trial by the investigator. (11) Any factor that may interfere with the ability to provide informed consent, comply with the study protocol, or attend scheduled follow-up visits.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-Free Survival (DFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS);Rate of recurrence;Total number of lymph nodes and metastatic rate;Surgical Complications;Quality of life score and patient-reported outcome (PRO); | — |
Countries
China
Contacts
Public ContactYouguo Dai
Yunnan Cancer Hospital (Peking University Cancer Hospital Yunnan Hospital / The Third Affiliated Hospital of Kunming Medical University)
Outcome results
None listed